These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 33414428)

  • 21. Pyrvinium Pamoate Induces Death of Triple-Negative Breast Cancer Stem-Like Cells and Reduces Metastases through Effects on Lipid Anabolism.
    Dattilo R; Mottini C; Camera E; Lamolinara A; Auslander N; Doglioni G; Muscolini M; Tang W; Planque M; Ercolani C; Buglioni S; Manni I; Trisciuoglio D; Boe A; Grande S; Luciani AM; Iezzi M; Ciliberto G; Ambs S; De Maria R; Fendt SM; Ruppin E; Cardone L
    Cancer Res; 2020 Oct; 80(19):4087-4102. PubMed ID: 32718996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The small G-protein RalA promotes progression and metastasis of triple-negative breast cancer.
    Thies KA; Cole MW; Schafer RE; Spehar JM; Richardson DS; Steck SA; Das M; Lian AW; Ray A; Shakya R; Knoblaugh SE; Timmers CD; Ostrowski MC; Chakravarti A; Sizemore GM; Sizemore ST
    Breast Cancer Res; 2021 Jun; 23(1):65. PubMed ID: 34118960
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Piperlongumine based nanomedicine impairs glycolytic metabolism in triple negative breast cancer stem cells through modulation of GAPDH & FBP1.
    Singh P; Sen K; Sa P; Khuntia A; Raghav SK; Swain RK; Sahoo SK
    Phytomedicine; 2024 Jan; 123():155181. PubMed ID: 38091824
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reprogramming Cancer Stem-like Cells with Nanoforskolin Enhances the Efficacy of Paclitaxel in Targeting Breast Cancer.
    Singh D; Singh P; Pradhan A; Srivastava R; Sahoo SK
    ACS Appl Bio Mater; 2021 Apr; 4(4):3670-3685. PubMed ID: 35014452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
    Tian J; Chen X; Fu S; Zhang R; Pan L; Cao Y; Wu X; Xiao H; Lin HJ; Lo HW; Zhang Y; Lin J
    Breast Cancer Res Treat; 2019 Jun; 175(3):553-566. PubMed ID: 30852762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting Hypoxia Sensitizes TNBC to Cisplatin and Promotes Inhibition of Both Bulk and Cancer Stem Cells.
    Sulaiman A; McGarry S; Chambers J; Al-Kadi E; Phan A; Li L; Mediratta K; Dimitroulakos J; Addison C; Li X; Wang L
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32806648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low Dose of Paclitaxel Combined with XAV939 Attenuates Metastasis, Angiogenesis and Growth in Breast Cancer by Suppressing Wnt Signaling.
    Shetti D; Zhang B; Fan C; Mo C; Lee BH; Wei K
    Cells; 2019 Aug; 8(8):. PubMed ID: 31416135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hyaluronic Acid-Targeted Stimuli-Sensitive Nanomicelles Co-Encapsulating Paclitaxel and Ritonavir to Overcome Multi-Drug Resistance in Metastatic Breast Cancer and Triple-Negative Breast Cancer Cells.
    Gote V; Sharma AD; Pal D
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination Organelle Mitochondrial Endoplasmic Reticulum Therapy (COMET) for Multidrug Resistant Breast Cancer.
    Milane LS; Dolare S; Ren G; Amiji M
    J Control Release; 2023 Nov; 363():435-451. PubMed ID: 37717658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Formulation of a triple combination gemcitabine plus romidepsin + cisplatin regimen to efficaciously and safely control triple-negative breast cancer tumor development.
    Pattarawat P; Wallace S; Pfisterer B; Odoi A; Wang HR
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):141-152. PubMed ID: 31865420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.
    Zhang T; Prasad P; Cai P; He C; Shan D; Rauth AM; Wu XY
    Acta Pharmacol Sin; 2017 Jun; 38(6):835-847. PubMed ID: 28216624
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transcriptome Profile Analysis of Triple-Negative Breast Cancer Cells in Response to a Novel Cytostatic Tetrahydroisoquinoline Compared to Paclitaxel.
    Gangapuram M; Mazzio EA; Redda KK; Soliman KFA
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299315
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer.
    Zheng MW; Zhang CH; Chen K; Huang M; Li YP; Lin WT; Zhang RJ; Zhong L; Xiang R; Li LL; Liu XY; Wei YQ; Yang SY
    Mol Cancer Ther; 2016 Mar; 15(3):366-78. PubMed ID: 26721945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nanoparticle-Mediated Co-Delivery of Notch-1 Antibodies and ABT-737 as a Potent Treatment Strategy for Triple-Negative Breast Cancer.
    Valcourt DM; Dang MN; Scully MA; Day ES
    ACS Nano; 2020 Mar; 14(3):3378-3388. PubMed ID: 32083466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synergistic effect of human uterine cervical mesenchymal stem cell secretome and paclitaxel on triple negative breast cancer.
    Eiro N; Fraile M; Escudero-Cernuda S; Sendon-Lago J; Gonzalez LO; Fernandez-Sánchez ML; Vizoso FJ
    Stem Cell Res Ther; 2024 Apr; 15(1):121. PubMed ID: 38664697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease.
    Sato K; Padgaonkar AA; Baker SJ; Cosenza SC; Rechkoblit O; Subbaiah DRCV; Domingo-Domenech J; Bartkowski A; Port ER; Aggarwal AK; Ramana Reddy MV; Irie HY; Reddy EP
    Nat Commun; 2021 Aug; 12(1):4671. PubMed ID: 34344863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elucidation of Altered Pathways in Tumor-Initiating Cells of Triple-Negative Breast Cancer: A Useful Cell Model System for Drug Screening.
    Christensen AG; Ehmsen S; Terp MG; Batra R; Alcaraz N; Baumbach J; Noer JB; Moreira J; Leth-Larsen R; Larsen MR; Ditzel HJ
    Stem Cells; 2017 Aug; 35(8):1898-1912. PubMed ID: 28600813
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced bioreduction-responsive diselenide-based dimeric prodrug nanoparticles for triple negative breast cancer therapy.
    He X; Zhang J; Li C; Zhang Y; Lu Y; Zhang Y; Liu L; Ruan C; Chen Q; Chen X; Guo Q; Sun T; Cheng J; Jiang C
    Theranostics; 2018; 8(18):4884-4897. PubMed ID: 30429875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sulforaphane Suppresses the Growth of Triple-negative Breast Cancer Stem-like Cells
    Castro NP; Rangel MC; Merchant AS; MacKinnon G; Cuttitta F; Salomon DS; Kim YS
    Cancer Prev Res (Phila); 2019 Mar; 12(3):147-158. PubMed ID: 30679159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.